Teva Launches 1% Sodium Hyaluronate
July 1, 2019 – Teva Pharmaceuticals has announced the launch of its 1% sodium hyaluronate product, which is approved by the U.S. FDA to treat pain caused by osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).
While not a generic, Teva’s product does contain the same active ingredient as Ferring BV’s Euflexxa® (1% sodium hyaluronate) and demonstrated similar safety and efficacy in a clinical trial. The product comes in a package containing three single-use pre-filled syringes that contain 2mL of 1% sodium hyaluronate each. The contents of a single syringe are injected intra-articularly into the affected knee joint once a week for three weeks. If both knees are affected by OA, only one should be treated at a time.
Teva’s product is available at the same average wholesale price (AWP) and wholesale acquisition cost (WAC) as brand name Euflexxa.